What could strengthen or challenge HEARTSCIENCES INC’s outlook?
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Higher potential upsideImproving expectations
Next-FY EPS estimate change · 30 days
Comparable estimates unavailable
+10% or more+5%0%−5%−10% or less
A matching fiscal period and sufficient coverage are required.
Higher risk of downsideWeakening expectations
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
How this is measured
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
Measure / period
Management expectations
Analyst expectations
Quarter ending 2026-10-31
Revenue
—
100,000
EPS
—
-0.62
Quarter ending 2027-01-31
Revenue
—
5,000
EPS
—
-0.61
Annual ending 2027-04-30
Revenue
—
17,100
EPS
—
-2.46
Annual ending 2028-04-30
Revenue
—
3.15M
EPS
—
-1.75
Management figures unavailable.
What the Thesis Depends On
5 published thesis conditions, with dated milestones shown separately.
Key Factor
Why It Matters
Current Status
Break Condition
Latest Evidence
Increase revenue above $14,700 by 2026-Q3
A primary condition in HEARTSCIENCES INC's published investment case. The stated target is >= $14,700 revenue by 2026-Q3.
Intact
revenue falls below $7,350 (half of peak $14,700) by 2026-Q3
Revenue: $2,100
FY2027-Q1; GAAP. Published target: >= $14,700 revenue by 2026-Q3. The stored target says 2026-Q3; this source reports FY2027-Q1. Fiscal/calendar alignment needs review.
Source published Sep 14, 20262,100 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement source
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated in 2 quarters including 2025-Q4 and 2026-Q2. The company reported no meaningful revenue for Fiscal 2026 and sustained net losses, with net income negative $2.75 million in 2026-Q4 and negative $3.17 million in 2027-Q1. Revenue was zero in 2026-Q4 and rose to $2.1 million in 2027-Q1. Management acknowledges financial challenges and is pursuing strategic alternatives. The trajectory shows limited progress with ongoing losses.
Delivery assessment Oct 24, 2026
Stabilize leadership after CEO and COO changes
Management is addressing leadership changes to stabilize operations.
Intact
additional CEO or COO departures before 2026-Q4
Direct metric needs a verified mapping
The published measure or accounting basis is not supported by an exact source binding.
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce operating losses from -$1.9 million in 2026-Q3
A primary condition in HEARTSCIENCES INC's published investment case. The stated target is operating loss less negative than -$1.9 million by 2026-Q3.
Intact
operating loss worsens beyond -$2.5 million by 2026-Q3
Operating income: $-2.939M
FY2027-Q1; GAAP. Published target: operating loss less negative than -$1.9 million by 2026-Q3. The stored target says 2026-Q3; this source reports FY2027-Q1. Fiscal/calendar alignment needs review.
Source published Sep 14, 2026-2,939,090 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement source
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management context
Stated in 2 quarters including 2025-Q4 and 2026-Q2. The company reported no meaningful revenue for Fiscal 2026 and sustained net losses, with net income negative $2.75 million in 2026-Q4 and negative $3.17 million in 2027-Q1. Revenue was zero in 2026-Q4 and rose to $2.1 million in 2027-Q1. Management acknowledges financial challenges and is pursuing strategic alternatives. The trajectory shows limited progress with ongoing losses.
Delivery assessment Oct 24, 2026
Maintain financing at or above $3.6 million secured in 2026-Q2
HeartSciences is actively improving its finances with $3.6 million secured in new financing.
Intact
financing falls below $2 million or no new financing by 2026-Q3
Direct metric needs a verified mapping
The published measure or accounting basis is not supported by an exact source binding.
Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Incoming Evidence
Compare these dated observations with the operating requirements above
Expectations trend
Same fiscal period
FY2028 · fiscal year ending 2028-04-30 · fmp
FY2028 EPS: comparable history unavailable.
FY2028 revenue: comparable history unavailable.
Exact estimates & source dates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
FY2028 estimate observations · fmp
Snapshot
EPS
Revenue
EPS / revenue analysts
2026-10-22
Unavailable
Unavailable
1 / 1
2026-10-23
Unavailable
Unavailable
1 / 1
2026-10-24
Unavailable
Unavailable
1 / 1
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
How this is measured
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Outlook in Brief
The evidence, the remaining questions, and what comes next
What's improving
No recovery evidence is reported in the available driver assessments.
Still unresolved / key risks
Increase revenue above $14,700 by 2026-Q3Revenue: $2,100
Stabilize leadership after CEO and COO changesDirect metric needs a verified mapping
Reduce operating losses from -$1.9 million in 2026-Q3Operating income: $-2.939M
Maintain financing at or above $3.6 million secured in 2026-Q2Direct metric needs a verified mapping
Complete merger agreements to expand market presenceDirect metric needs a verified mapping
Next proof point
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Risk observations as of Oct 23, 2026 · 97 daily observations. Historical moves are not forecasts.
Read detailed Outlook Company context, assumptions & risks
HEARTSCIENCES INC outlook in detail
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
What kind of bet this is
This is a speculative, loss-making business with elevated risk, weak recent performance, and volatile management. The thesis is on watch: stated operating and product milestones offer some progress, but the evidence does not yet show a consistent financial turnaround.
What's priced into HEARTSCIENCES INC
The snapshot gives no valuation multiple or peer comparison, so it is not possible to describe HSCS as cheap, fair, or expensive. It also provides no clear account of the market’s expectations; the low fragility tier only indicates that no listed fragility checks were triggered.
What the fundamentals likely do
Near term, earnings execution is a concern: HSCS recently missed earnings, has a run of consecutive misses, and the snapshot assigns a 51% miss probability for the next report. Over the multi-year view, Fortitude reported mining and revenue activity, while MyoVista reached full commercial launch and received FDA clearance for its wavECG device without the AI algorithm; execution and financial impact remain uncertain.
What HEARTSCIENCES INC hinges on
A key swing factor is whether the merger with Fortitude closes in Q4 2026, subject to shareholder approval and customary conditions, and whether the mining platform continues to scale. The other major test is whether MyoVista’s AI-enabled ECG plans gain traction; a guidance cut would add a near-term negative, while continued strength from healthcare sector leaders could support the sector backdrop.
Bottom line
The multi-year view remains a watch case, not a demonstrated turnaround: merger completion and delivery across mining and ECG matter, while weak results and repeated earnings misses remain material risks. Not investment advice.
Source: QuarterlyIQ weekly Outlook · Week ending Oct 24, 2026 · Carried forward
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
